The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

Intellia Therapeutics (NTLA) stock plummets after the company's Q3 updates indicate a patient deeath in a Phase 3 for its nex ...

The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on ...

Graduate student Arjun Ojha Kshetry and colleagues combined two key genes: WIND1, which reprograms cells near a wound, and ...

The UK regulator is creating a new framework for how it will approve rare disease treatments, which it intends to publish in ...

California biotech company Cellipont has opened a new 76,000 square foot cell therapy headquarters in The Woodlands' booming ...

Jarome and his team found that aging disrupts K63 polyubiquitination in two distinct areas of the brain. In the hippocampus, ...

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

Many plants including cocoa, coffee and avocado cannot be gene-edited but a technique involving grafting could change that, ...

The Kanazawa team led by Katsuya Sakai, discovered that CHD1 uses a flexible region to form tiny liquid-like droplets, called condensates, that act as hubs for controlling the activity of crucial ...